Antibiotic Resistance in Community-Acquired Pneumonia Pathogens

Seminars in Respiratory and Critical Care Medicine

Volumn 37, Issue 6, 2016, Pages 829-838

  Wunderink, Richard G ^a   Yin, Yudong ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

antibiotic resistance; community acquired pneumonia; hemophilus influenza; pneumococcus; pneumonia; S. aureus

Indexed keywords

BETA LACTAM; CEPHALOSPORIN; CLINDAMYCIN; MACROLIDE; PNEUMOCOCCUS VACCINE; QUINOLONE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CHLAMYDIA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA; LEGIONELLA PNEUMOPHILA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOPLASMA PNEUMONIAE; NONHUMAN; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; BACTERIAL PNEUMONIA; BETA-LACTAM RESISTANCE; COMMUNITY ACQUIRED INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; STREPTOCOCCUS PNEUMONIAE;

EID: 85005939292     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0036-1593753     Document Type: Article

References (75)

1. Shindo Y Ito R Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia Am J Respir Crit Care Med 2013 188 8 985 995
2. Attridge R T Frei C R Restrepo M I, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia Eur Respir J 2011 38 4 878 887
3. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 2005 171 4 388 416
4. Griffin M R Zhu Y Moore M R Whitney C G Grijalva C G U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination N Engl J Med 2013 369 2 155 163
5. Welte T Torres A Nathwani D Clinical and economic burden of community-acquired pneumonia among adults in Europe Thorax 2012 67 1 71 79
6. Jain S Self W H Wunderink R G, et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults N Engl J Med 2015 373 5 415 427
7. Charles P G Whitby M Fuller A J, et al; Australian CAP Study Collaboration. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy Clin Infect Dis 2008 46 10 1513 1521
8. Rice L B Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones Mayo Clin Proc 2012 87 2 198 208
9. Jacobs M R Koornhof H J Robins-Browne R M, et al. Emergence of multiply resistant pneumococci N Engl J Med 1978 299 14 735 740
10. Flamm R K Sader H S Farrell D J Jones R N Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers Antimicrob Agents Chemother 2014 58 4 2468 2471
11. Jones R N Sader H S Mendes R E Flamm R K Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011) Diagn Microbiol Infect Dis 2013 75 1 107 109
12. Wang H Chen M Xu Y, et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010 Int J Antimicrob Agents 2011 38 5 376 383
13. Ohno A Ishii Y Kobayashi I Yamaguchi K Antibacterial activity and PK/PD of ceftriaxone against penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae isolates from patients with community-acquired pneumonia J Infect Chemother 2007 13 5 296 301
14. Garcia-Vidal C Ardanuy C Tubau F, et al. Pneumococcal pneumonia presenting with septic shock: host-and pathogen-related factors and outcomes Thorax 2010 65 1 77 81
15. Moroney J F Fiore A E Harrison L H, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance Clin Infect Dis 2001 33 6 797 805
16. Cillóniz C Ewig S Polverino E, et al. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes Clin Microbiol Infect 2012 18 11 1134 1142
17. CLSI 2008. Performance Standards for Antimicrobial Susceptibility Testing CLSI Document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA
18. Gillespie S H Antibiotic resistance in the absence of selective pressure Int J Antimicrob Agents 2001 17 3 171 176
19. Andersson D I The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 2006 9 5 461 465
20. Ríos Dueñas E Rodríguez-Avial I Picazo J J In vitro activity of ceftobiprole and seven other antimicrobial agents against invasive Streptococcus pneumoniae isolates in Spain Eur J Clin Microbiol Infect Dis 2011 30 12 1621 1625
21. Isozumi R Ito Y Ishida T, et al; Kansai Community Acquired Pneumococcal Pneumonia Study Groupe. Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan J Clin Microbiol 2007 45 5 1440 1446
22. Waterer G W Wunderink R G Jones C B Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy Chest 2000 118 6 1839 1840
23. Lonks J R Garau J Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae Clin Infect Dis 2002 35 5 556 564
24. Yanagihara K Izumikawa K Higa F, et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection Intern Med 2009 48 7 527 535
25. Kohno S Tateda K Kadota J, et al. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia J Infect Chemother 2014 20 3 199 207
26. Cilloniz C Albert R K Liapikou A, et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia Am J Respir Crit Care Med 2015 191 11 1265 1272
27. Zarogoulidis P Papanas N Kioumis I Chatzaki E Maltezos E Zarogoulidis K Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases Eur J Clin Pharmacol 2012 68 5 479 503
28. Olsen K M San Pedro G Gann L P Gubbins P O Halinski D M Campbell G D Jr Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses Antimicrob Agents Chemother 1996 40 11 2582 2585
29. Fuller J D Low D E A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance Clin Infect Dis 2005 41 1 118 121
30. Tomczyk S Lynfield R Schaffner W, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-Valent pneumococcal conjugate vaccine Clin Infect Dis 2016 62 9 1119 1125
31. Hampton L M Farley M M Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines J Infect Dis 2012 205 3 401 411
32. Arnold F W Summersgill J T Lajoie A S, et al; Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia Am J Respir Crit Care Med 2007 175 10 1086 1093
33. Morozumi M Hasegawa K Kobayashi R, et al. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation Antimicrob Agents Chemother 2005 49 6 2302 2306
34. Cao B Zhao C J Yin Y D, et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China Clin Infect Dis 2010 51 2 189 194
35. Zheng X Lee S Selvarangan R, et al. Macrolide-resistant Mycoplasma pneumoniae, United States Emerg Infect Dis 2015 21 8 1470 1472
36. Zhou Z Li X Chen X, et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China Antimicrob Agents Chemother 2015 59 2 1048 1051
37. Yin Y D Cao B Wang H, et al. [Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China] [in Chinese] Zhonghua Jie He He Hu Xi Za Zhi 2013 36 12 954 958
38. Miyashita N Akaike H Teranishi H Ouchi K Okimoto N Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults: clinical findings, drug susceptibility, and therapeutic efficacy Antimicrob Agents Chemother 2013 57 10 5181 5185
39. Kurata S Taguchi H Sasaki T Fujioka Y Kamiya S Antimicrobial and immunomodulatory effect of clarithromycin on macrolide-resistant Mycoplasma pneumoniae J Med Microbiol 2010 59 (Pt 6): 693 701
40. Burdet C Lepeule R Duval X, et al. Quinolones versus macrolides in the treatment of legionellosis: a systematic review and meta-analysis J Antimicrob Chemother 2014 69 9 2354 2360
41. Critchley I A Jones M E Heinze P D, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe Clin Microbiol Infect 2002 8 4 214 221
42. Edelstein P H Edelstein M A Lehr K H Ren J In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia J Antimicrob Chemother 1996 37 1 117 126
43. Almahmoud I Kay E Schneider D Maurin M Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila J Antimicrob Chemother 2009 64 2 284 293
44. Bruin J P Koshkolda T IJzerman E P, et al. Isolation of ciprofloxacin-resistant Legionella pneumophila in a patient with severe pneumonia J Antimicrob Chemother 2014 69 10 2869 2871
45. Shadoud L Almahmoud I Jarraud S, et al. Hidden selection of bacterial resistance to fluoroquinolones in vivo: the case of Legionella pneumophila and humans EBioMedicine 2015 2 9 1179 1185
46. Kutlin A Kohlhoff S Roblin P Hammerschlag M R Riska P Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis Antimicrob Agents Chemother 2005 49 3 903 907
47. Riska P F Kutlin A Ajiboye P Cua A Roblin P M Hammerschlag M R Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae Antimicrob Agents Chemother 2004 48 9 3586 3590
48. Chambers H F Deleo F R Waves of resistance: Staphylococcus aureus in the antibiotic era Nat Rev Microbiol 2009 7 9 629 641
49. Chambers H F The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001 7 2 178 182
50. Kollef M H Shorr A Tabak Y P Gupta V Liu L Z Johannes R S Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia Chest 2005 128 6 3854 3862
51. Smith S B Ruhnke G W Weiss C H Waterer G W Wunderink R G Trends in pathogens among patients hospitalized for pneumonia from 1993 to 2011 JAMA Intern Med 2014 174 11 1837 1839
52. Labelle A J Arnold H Reichley R M Micek S T Kollef M H A comparison of culture-positive and culture-negative health-care-associated pneumonia Chest 2010 137 5 1130 1137
53. Self W H Wunderink R G Williams D J, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes Clin Infect Dis 2016 63 3 300 309
54. Mendes R E Sader H S Deshpande L M Diep B A Chambers H F Jones R N Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid J Clin Microbiol 2010 48 2 568 574
55. Gillet Y Issartel B Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients Lancet 2002 359 9308 753 759
56. Gillet Y Vanhems P Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin Clin Infect Dis 2007 45 3 315 321
57. Wunderink R G Niederman M S Kollef M H, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study Clin Infect Dis 2012 54 5 621 629
58. Sicot N Khanafer N Meyssonnier V, et al. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia--results of a prospective observational study Clin Microbiol Infect 2013 19 3 E142 E148
59. File T M Jr Low D E Eckburg P B, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia Clin Infect Dis 2010 51 12 1395 1405
60. Gadsby N J Russell C D McHugh M P, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia Clin Infect Dis 2016 62 7 817 823
61. Desai S Jamieson F B Patel S N, et al. The epidemiology of invasive Haemophilus influenzae non-serotype B disease in Ontario, Canada from 2004 to 2013 PLoS One 2015 10 11 e0142179
62. Puig C Calatayud L Martí S, et al. Molecular epidemiology of nontypeable Haemophilus influenzae causing community-acquired pneumonia in adults PLoS One 2013 8 12 e82515
63. Resman F Ristovski M Forsgren A, et al. Increase of β-lactam-resistant invasive Haemophilus influenzae in Sweden, 1997 to 2010 Antimicrob Agents Chemother 2012 56 8 4408 4415
64. File T M Jr Rewerska B Vucinić-Mihailović V, et al; SOLITAIRE-IV Pneumonia Team. SOLITAIRE-IV: A randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia Clin Infect Dis 2016 ciw490
65. Torres A Blasi F Peetermans W E Viegi G Welte T The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review Eur J Clin Microbiol Infect Dis 2014 33 7 1065 1079
66. von Baum H Welte T Marre R Suttorp N Ewig S; CAPNETZ study group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Eur Respir J 2010 35 3 598 605
67. Sousa D Justo I Domínguez A, et al. Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome Clin Microbiol Infect 2013 19 2 187 192
68. Wunderink R G Community-acquired pneumonia versus healthcare-associated pneumonia. The returning pendulum Am J Respir Crit Care Med 2013 188 8 896 898
69. Rodríguez-Avial I Ramos B Ríos E Cercenado E Ordobás M Sanz J C; Madrid Streptococcus pneumoniae Microbiological Group. Clonal spread of levofloxacin-resistant streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009 Antimicrob Agents Chemother 2011 55 5 2469 2471
70. Patel S N McGeer A Melano R, et al; Canadian Bacterial Surveillance Network. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada Antimicrob Agents Chemother 2011 55 8 3703 3708
71. Golden A R Rosenthal M Fultz B, et al. Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13 J Antimicrob Chemother 2015 70 8 2199 2202
72. Adam H J Baxter M R Davidson R J, et al; Canadian Antimicrobial Resistance Alliance (CARA). Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals J Antimicrob Chemother 2013 68 01 i31 i37
73. Hu F Zhu D Wang F Morrissey I Wang J Torumkuney D Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 and 2013-14 in China J Antimicrob Chemother 2016 71 01 i33 i43
74. Pérez-Trallero E Martín-Herrero J E Mazón A, et al; Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007) Antimicrob Agents Chemother 2010 54 7 2953 2959
75. Hong K B Choi E H Lee H J, et al. Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000-2011 Emerg Infect Dis 2013 19 8 1281 1284